Construction of a prognostic model based on genome-wide methylation analysis of miRNAs for hepatocellular carcinoma

Papers of special note have been highlighted as: • of interest

References

• 1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 136(2), 215–233 (2009).
  Medline CASGoogle Scholar
• 2. Kozaki K, Inazawa J. Tumor-suppressive microRNA silenced by tumor-specific DNA hypermethylation in cancer cells. Cancer Sci. 103(5), 837–845 (2012).
  Medline CASGoogle Scholar
• 3. Shang R, Lee S, Senavirathne G, Lai EC. microRNAs in action: biogenesis, function and regulation. Nat. Rev. Genet. 24, 816–833 (2023).
  Medline CASGoogle Scholar
• 4. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409(6818), 363–366 (2001).
  Medline CASGoogle Scholar
• 5. Lee Y, Jeon K, Lee JT et al. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 21(17), 4663–4670 (2002).
  Medline CASGoogle Scholar
• 6. Lee Y, Kim M, Han J et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23(20), 4051–4060 (2004).
  Medline CASGoogle Scholar
• 7. Kita Y, Vincent K, Natsugoe S et al. Epigenetically regulated microRNAs and their prospect in cancer diagnosis. Expert Rev. Mol. Diagn. 14(6), 673–683 (2014).
  Medline CASGoogle Scholar
• 8. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 73(2), 473–477 (2013).
  Medline CASGoogle Scholar
• 9. Zare M, Bastami M, Solali S, Alivand MR. Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J. Cell Physiol. 233(5), 3729–3744 (2018).
  Medline CASGoogle Scholar
• 10. Arif KMT, Elliott EK, Haupt LM, Griffiths LR. Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets. Cancers (Basel) 12(10), (2020).
  Google Scholar
• 11. Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv. Drug Deliv. Rev. 81, 62–74 (2015).
  Medline CASGoogle Scholar
• 12. Yu Z, Cheng AS. Epigenetic deregulation of microRNAs: new opportunities to target oncogenic signaling pathways in hepatocellular carcinoma. Curr. Pharm. Des. 19(7), 1192–1200 (2013). • Reflects the need for our research.
  Medline CASGoogle Scholar
• 13. Liu A, Wu Q, Peng D et al. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation. Med. Res. Rev. 40(5), 1973–2018 (2020).
  Medline CASGoogle Scholar
• 14. Li XY, Zhao ZJ, Wang JB et al. m7G methylation-related genes as biomarkers for predicting overall survival outcomes for hepatocellular carcinoma. Front. Bioeng. Biotechnol. 10, 849756 (2022).
  MedlineGoogle Scholar
• 15. Li D, Li K, Zhang W et al. The m6A/m5C/m1A regulated gene signature predicts the prognosis and correlates with the immune status of hepatocellular carcinoma. Front. Immunol. 13, 918140 (2022).
  Medline CASGoogle Scholar
• 16. Li GX, Ding ZY, Wang YW et al. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma. J. Cell Physiol. 234(7), 11942–11950 (2019).
  Medline CASGoogle Scholar
• 17. Liu S, Miao C, Liu J et al. Four differentially methylated gene pairs to predict the prognosis for early stage hepatocellular carcinoma patients. J. Cell Physiol. 233(9), 6583–6590 (2018).
  Medline CASGoogle Scholar
• 18. Gan B, He Y, Ma Y et al. Identification of a novel lncRNA prognostic signature and analysis of functional lncRNA AC115619.1 in hepatocellular carcinoma. Front. Pharmacol. 14, 1167418 (2023).
  Medline CASGoogle Scholar
• 19. Mi JX, Zhang YN, Lai Z et al. Principal component analysis based on nuclear norm minimization. Neural Netw. 118, 1–16 (2019).
  MedlineGoogle Scholar
• 20. Jolliffe IT, Cadima J. Principal component analysis: a review and recent developments. Philos. Trans. A Math. Phys. Eng. Sci. 374(2065), 20150202 (2016).
  MedlineGoogle Scholar
• 21. Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 32(30), 5381–5397 (2013).
  MedlineGoogle Scholar
• 22. Eaton A, Therneau T, Le-Rademacher J. Designing clinical trials with (restricted) mean survival time endpoint: practical considerations. Clin. Trials 17(3), 285–294 (2020).
  MedlineGoogle Scholar
• 23. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 26(8), 1364–1370 (2008).
  MedlineGoogle Scholar
• 24. Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics 8(3), 389–399 (2016).
  CASGoogle Scholar
• 25. Fu S, Debes JD, Boonstra A. DNA methylation markers in the detection of hepatocellular carcinoma. Eur. J. Cancer 191, 112960 (2023).
  Medline CASGoogle Scholar
• 26. Zhang R, Zhang LJ, Yang ML et al. Potential role of microRNA-223-3p in the tumorigenesis of hepatocellular carcinoma: a comprehensive study based on data mining and bioinformatics. Mol. Med. Rep. 17(2), 2211–2228 (2018).
  Medline CASGoogle Scholar
• 27. Zhou Y, Chen E, Tang Y et al. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis. 10(11), 843 (2019).
  MedlineGoogle Scholar
• 28. Dong Z, Qi R, Guo X et al. MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation. Biochem. Biophys Res. Commun. 483(1), 630–637 (2017).
  Medline CASGoogle Scholar
• 29. Tang X, Yang W, Shu Z et al. MicroRNA-223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7. Oncol. Rep. 41(2), 1231–1237 (2019).
  Medline CASGoogle Scholar
• 30. Xu J, An P, Winkler CA, Yu Y. Dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma: potential as biomarkers and therapeutic targets. Front. Oncol. 10, 1271 (2020).
  MedlineGoogle Scholar
• 31. Yu G, Chen X, Chen S et al. MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells. J. Transl. Med. 14(1), 122 (2016).
  Medline CASGoogle Scholar
• 32. Wang Q, Xiong F, Wu G et al. Gene body methylation in cancer: molecular mechanisms and clinical applications. Clin. Epigenetics 14(1), 154 (2022).
  MedlineGoogle Scholar
• 33. Carreras-Gallo N, Dwaraka VB, Cáceres A et al. Impact of tobacco, alcohol, and marijuana on genome-wide DNA methylation and its relationship with hypertension. Epigenetics 18(1), 2214392 (2023).
  MedlineGoogle Scholar
• 34. Hoang TT, Lee Y, McCartney DL et al. Comprehensive evaluation of smoking exposures and their interactions on DNA methylation. EBioMedicine 100, 104956 (2024).
  Medline CASGoogle Scholar
• 35. Su J, Song S, Dou Y et al. Methylation specific enzyme-linked oligonucleotide assays (MS-ELONA) for ultrasensitive DNA methylation analysis. Biosens. Bioelectron. 238, 115587 (2023).
  Medline CASGoogle Scholar
• 36. Jiang Y, Miao P. DNA dumbbell and chameleon silver nanoclusters for miRNA logic operations. Research (Wash DC) 2020, 1091605 (2020).
  CASGoogle Scholar
• 37. Li Y, Cai M, Zhang W et al. Cas12a-based direct visualization of nanoparticle-stabilized fluorescence signal for multiplex detection of DNA methylation biomarkers. Biosens. Bioelectron 244, 115810 (2024).
  Medline CASGoogle Scholar